Bayesian Dosing Benefits.

Precision Dosing

“[Aminoglycoside Bayesian dose individualization] is a well-accepted practice… [Further studies] may not be feasible for ethical reasons.” – Ho et al.

Precision dosing using Bayesian dose individualization has been shown to have such significant benefits that some leading researchers believe that further clinical trials may be unethical, due to the control arm being required to receive substandard treatment. 

Enhance Outcomes

The following papers are just some of the randomized clinical trials that show the patient benefits of precision dosing and dose-individualization:

1. Increased survival for childhood leukemia patients.
2. Improved survival for septic patients.
3. Increased patients in therapeutic range (chemotherapy).
4. Increased proportion of patients in the therapeutic range:
   • Warfarin
   • Enoxaparin
   • Vancomycin
   • Aminoglycosides
5. Decreased time to therapeutic stabilization.
6. Shortened febrile periods:
   • Gentamicin
   • Aminoglycosides

Reduce Adverse Events

Precision dosing reduces adverse events. The following RCTs demonstrate some of these benefits:

1. Reduced risk of toxic drug levels.
2. Reduction in bleeding events.
3. Reduction in bruising events.
4. Halve side-effects for chemotherapy patients.
5. Decreased discontinuation due to adverse events.
6. Decreased nephrotoxicity:
   • Gentamicin
   • Vancomycin

Reduce Costs

Improving patient outcomes and reducing adverse events is highly cost-effective. The studies below quantify the cost-benefits of precision dosing:

1. Cost-benefit ratio of between 4:1 and 52:1. (Review).
2. Save $2,500 (USD, 2012) per patient.
3. Substantial overall savings due to lowered mortality.
4. Reduce hospital stay length by more than 6 days per patient.
5. 4.6 day reduction in hospital stay length.